Zai Lab Ltd
09688
Company Profile
Business description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Contact
4560 Jinke Road
Jinchuang Plaza, Building 1, 4th Floor
Pudong
Shanghai201210
CHNT: +86 2161632588
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,844
Stocks News & Analysis
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
stocks
Why ANZ changes aren’t just about cutting costs
The banking major needs to prevent key product offerings from falling further behind the competition.
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,095.20 | 28.80 | 0.32% |
| CAC 40 | 7,772.88 | 23.49 | 0.30% |
| DAX 40 | 23,775.52 | 57.07 | 0.24% |
| Dow JONES (US) | 45,711.34 | 196.39 | 0.43% |
| FTSE 100 | 9,261.54 | 19.01 | 0.21% |
| HKSE | 26,200.26 | 262.13 | 1.01% |
| NASDAQ | 21,879.49 | 80.79 | 0.37% |
| Nikkei 225 | 43,837.67 | 378.38 | 0.87% |
| NZX 50 Index | 13,276.24 | 22.51 | 0.17% |
| S&P 500 | 6,512.61 | 17.46 | 0.27% |
| S&P/ASX 200 | 8,830.40 | 40.00 | 0.46% |
| SSE Composite Index | 3,812.22 | 4.93 | 0.13% |